Transformative transactions and engagements
Locust Walk has a robust record of success in closing high-value transactions for multiple clients. Our work spans the spectrum of therapeutic areas and modalities, from cutting edge gene therapies in oncology to over-the-counter consumer pharmaceutical products. A selection of our engagements appears below. Please click on each case study or news release for greater detail about each transformative transaction. Contact us if you would like to learn more.
PARTNER: IOVaxis Therapeutics
TRANSACTION: Sell-side engagement leading to option agreement for greater Chinese rights to a RAS peptide cancer vaccine
$100M in Milestones and Double Digit Royalities
PARTNER: SymBio Pharmaceuticals Limited
TRANSACTION: Exclusive global licensing agreement with SymBio Pharmaceuticals for Brincidofovir
Up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones
CLIENT: Mesa Biotech
Growth capital for point-of-care diagnostic product company
$20M Private Placement
CLIENT: Pernix Therapeutics
PARTNER: Orexigen Therapeutics
Buy-side advisor to Pernix Therapeutics in its acquisition of Orexigen Therapeutics for $73.5M
CLIENT: HealthCare Royalty Partners (HCRP)
PARTNER: Albireo Pharma Inc.
Advised on commercial potential of elobixibat (a new drug for chronic constipation) in Japan leading to HCRP purchasing royalty stream.
CLIENT: Corsair Pharma
PARTNER: United Therapeutics
Corsair has entered into an exclusive IP licensing agreement along with an equity investment and option to acquire with United Therapeutics. Locust Walk served as the Financial Advisor to Corsair.
Sell-Side process for NeoCart® leading to a Japan licensing agreement with MEDINET
$10M upfront, $87M Total w/Milestones plus Royalties
PARTNER: Asahi Kasei Pharma
Facilitated negotiations between the US and Japan leading to the partnering in Japan of sarilumab (IL-6R mAb), a novel therapy for rheumatoid arthritis.
CLIENT: TesoRx Pharma LLC
PARTNER: ASKA Pharmaceutical
Advised on expansion of existing collaboration on TSX-011 (oral testosterone) by adding SE Asia territory and expanding scope to CDGP indication, in addition to ASKA equity investment in TesoRx.
CLIENT: Spero Therapeutics
PARTNER: Meiji Seika Pharma Co.,Ltd
Advised on Japan buy-side process leading to exclusive License Agreement for Meiji’s novel oral carbapenem, SPR-994
CLIENT: NeoTX Therapeutics
PARTNER: Active Biotech
Buy-side licensing agreement for ANYARA
CLIENT: Strategic Science & Technologies, LLC
Sell-side license for Canadian rights of IbuCream
CLIENT: Advaxis Immunotherapies
Immuno- Oncology Advisor